title: [Prognostic factors for the efficacy of Silodosin in the treatment of symptomatic Benign Prostatic Hyperplasia. Subanalysis of the URAL study.]
abstract: OBJECTIVE
  To identify the prognostic factors influencing the clinical and urodynamics results on symptomatic benign prostatic hypertrophy (BHP) treatment in a series of patients with silodosin therapy from the URAL study.
  
  
  METHODS
  A retrospective study was performed in a cohort of 318 patients with BPH which underwent silodosine treatment, during at least 12 weeks.
  
  
  RESULTS
  Univariate analysis demonstrated that the variables in relationship with a decrease of urinary symptoms` punctuation postreatment (measured with the IPSS Questionnaire), a maximum peak flow (Q max) postreatment equal or superior to 15 ml/s, a postreatment postvoid residual lower to 100 ml, and a postreatment obstruction index ( Bladder Outlet Obstruction Index: BOOI) equal or lower to 20 cm H2O, presented such both as a clinical and urodynamic character. The multivariate analysis demonstrated that a decreased punctuation of IPSS Questionnaire postreatment was in relationship to: a pretreatment cystometry bladder capacity (direct relationship), pretreatment Qmax (direct relationship), pretreatment postvoid residual (inverse relationship), and pretreatment BOOI (inverse relationship).
  
  
  CONCLUSIONS
  The urodynamic study was very useful in the assessment of the prognostic factors in these patients.
authors.affiliation: Servicio de Urología. Hospital Clínico San Carlos. Madrid. España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Salinas-Casado
authors.affiliation: Servicio de Urología. Hospital Nacional de Parapléjicos. Toledo. España.
authors.forename: Miguel
authors.initials: M
authors.lastname: Vírseda-Chamorro
authors.affiliation: Servicio de Urología. Hospital Universitario Sanitas La Moraleja. Madrid. España.
authors.forename: Santiago
authors.initials: S
authors.lastname: Méndez-Rubio
authors.affiliation: Servicio de Urología. Hospital Universitario de Parla. Madrid. España.
authors.forename: Marcos
authors.initials: M
authors.lastname: Luján-Galán
authors.affiliation: Servicio de Urología. Hospital Nacional de Parapléjicos. Toledo. España.
authors.forename: Manuel
authors.initials: M
authors.lastname: Esteban-Fuertes
authors.affiliation: Servicio de Urología. Hospital Clínico San Carlos. Madrid. España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Moreno-Sierra
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D007211:Indoles; C095285:silodosin